Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390806 · ClinicalTrials.gov registry record · Phase 3
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Phase 3 study of Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 472
- Enrollment target
- 20
- Study locations
NCT00390806 is a Phase 3 study of Lung Cancer, Non-Small Cell that has completed, run by GlaxoSmithKline. The registered enrollment target is 472 participants, above the 284-participant average among 10 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (66% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT00390806, a Phase 3 study of Lung Cancer, Non-Small Cell, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 472 participants
- Enrollment target
- 20
- Study locations
Study Summary
The current prognosis for patients with metastatic brain cancer from NSCLC is very poor. The current standard treatment for this disease is radiation therapy to the brain. The goal of the current study is to test whether the combination of orally administered HYCAMTIN capsules and whole brain radiation therapy will prolong the survival time of patients with this potentially serious condition.
Conditions Studied
Interventions
- RADIATION Radiation
- DRUG HYCAMTIN, oral capsules
Study Locations (20)
Illinois
- GSK Investigational Site - Chicago
- GSK Investigational Site - Elk Grove Village
- GSK Investigational Site - Galesburg
- GSK Investigational Site - Park Ridge
- GSK Investigational Site - Rockford
- GSK Investigational Site - Skokie
California
- GSK Investigational Site - Anaheim
- GSK Investigational Site - Duarte
- GSK Investigational Site - Pleasant Hill
Florida
- GSK Investigational Site - Lakeland
- GSK Investigational Site - Tampa
- GSK Investigational Site - Tampa
Alabama
- GSK Investigational Site - Birmingham
Arizona
- GSK Investigational Site - Glendale
Arkansas
- GSK Investigational Site - Hot Springs
Colorado
- GSK Investigational Site - Aurora
Indiana
- GSK Investigational Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 472 participants |
| Start Date | 2006-12 |
| Est. Completion | 2013-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00390806
The ClinicalTrials.gov registry entry for NCT00390806 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 472 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 284-participant average among 10 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (66% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer, Non-Small Cell appearing as the primary indexed condition, and to 2 interventions - of which Radiation is the first listed.
NCT00390806 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Illinois, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00390806 about?
NCT00390806 is a clinical study titled "Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer". The current prognosis for patients with metastatic brain cancer from NSCLC is very poor. The current standard treatment for this disease is radiation therapy to the brain. The goal of the current study is to test whether the combination of orally administered HYCAMTIN capsules and whole brain radiat...
What is the current status of trial NCT00390806?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 472 participants. The study started on 2006-12. Estimated completion is 2013-09.
What conditions does trial NCT00390806 study?
This clinical trial studies the following conditions: Lung Cancer, Non-Small Cell.
What interventions are being tested in trial NCT00390806?
The interventions under investigation include: Radiation (RADIATION), HYCAMTIN, oral capsules (DRUG).
Who is sponsoring clinical trial NCT00390806?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00390806 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer, Non-Small Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
Engagement of Veterans With Lung Cancer
RECRUITING · NA
-
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
-
Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.